Effectiveness and Comparison of CAR-NK in Multiple Myeloma
DOI:
https://doi.org/10.58445/rars.690Keywords:
Chimeric Antigen Receptor, Natural Killer, Lymphocytes, Multiple MyelomaAbstract
Multiple myeloma (MM) is a deadly cancer of the plasma cells, which disrupts antibody production and overall health. Commonly used treatments for MM include chemotherapy, radiation therapy, and a less used CAR-T therapy. Although these therapies are mostly effective, debilitating and severe side effects can emerge. CAR-NK therapy poses a promising treatment for patients with MM, as the CAR-NK cytokine profile allows for lower side effects compared to CAR-T and still shows strong anti-tumor action. This review evaluates the mechanism and function of CAR-NK receptors and their efficacy against multiple myeloma compared to other therapies.
References
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2002). Innate Immunity. In Molecular Biology of the Cell. 4th edition. Garland Science. https://www.ncbi.nlm.nih.gov/books/NBK26846/
Albinger, N., Hartmann, J., & Ullrich, E. (2021). Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Therapy, 28(9), 513–527. https://doi.org/10.1038/s41434-021-00246-w
Apheresis variability control. (n.d.). Cytiva. Retrieved October 29, 2023, from https://www.cytivalifesciences.com/en/us/solutions/cell-therapy/knowledge-center/resources/apheresis-variability-control
CAR T cell principles. (2018, June 28). Carl DeSelm Lab. https://deselmlab.wustl.edu/research/car-t-cell-principles/
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013). B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(8), 2048–2060. https://doi.org/10.1158/1078-0432.CCR-12-2422
Casucci, M., & Bondanza, A. (2011). Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes. Journal of Cancer, 2, 378–382. https://doi.org/10.7150/jca.2.378
Contributors, W. E. (n.d.). Radiation Therapy for Treating Multiple Myeloma. WebMD. Retrieved October 29, 2023, from https://www.webmd.com/cancer/multiple-myeloma/multiple-myeloma-radiation
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014). Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells. Immunological Reviews, 257(1), 10.1111/imr.12131. https://doi.org/10.1111/imr.12131
Elahi, R., Heidary, A. H., Hadiloo, K., & Esmaeilzadeh, A. (2021). Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects. Stem Cell Reviews and Reports, 17(6), 2081. https://doi.org/10.1007/s12015-021-10246-3
Gunturi, A., Berg, R. E., & Forman, J. (2004). The role of CD94/NKG2 in innate and adaptive immunity. Immunologic Research, 30(1), 29–34. https://doi.org/10.1385/IR:30:1:029
Habib, S., Tariq, S. M., & Tariq, M. (2019). Chimeric Antigen Receptor-Natural Killer Cells: The Future of Cancer Immunotherapy. The Ochsner Journal, 19(3), 186–187. https://doi.org/10.31486/toj.19.0033
Hu, Y., Tian, Z., & Zhang, C. (2018). Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacologica Sinica, 39(2), Article 2. https://doi.org/10.1038/aps.2017.125
Hudspeth, K., Silva-Santos, B., & Mavilio, D. (2013). Natural Cytotoxicity Receptors: Broader Expression Patterns and Functions in Innate and Adaptive Immune Cells. Frontiers in Immunology, 4, 69. https://doi.org/10.3389/fimmu.2013.00069
Khawar, M. B., & Sun, H. (2021). CAR-NK Cells: From Natural Basis to Design for Kill. Frontiers in Immunology, 12. https://www.frontiersin.org/articles/10.3389/fimmu.2021.707542
Leddon, S. A., Fettis, M. M., Abramo, K., Kelly, R., Oleksyn, D., & Miller, J. (2020). The CD28 Transmembrane Domain Contains an Essential Dimerization Motif. Frontiers in Immunology, 11, 1519. https://doi.org/10.3389/fimmu.2020.01519
Leivas, A., Rio, P., Mateos, R., Paciello, M. L., Garcia-Ortiz, A., Fernandez, L., Perez-Martinez, A., Lee, D. A., Powell, D. J., Valeri, A., & Martinez-Lopez, J. (2018). NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells. Blood, 132, 590. https://doi.org/10.1182/blood-2018-99-114522
Mandelboim, O., Malik, P., Davis, D. M., Jo, C. H., Boyson, J. E., & Strominger, J. L. (1999). Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proceedings of the National Academy of Sciences, 96(10), 5640–5644. https://doi.org/10.1073/pnas.96.10.5640
Multiple Myeloma—Statistics. (2012, June 25). Cancer.Net. https://www.cancer.net/cancer-types/multiple-myeloma/statistics
Multiple myeloma—Symptoms and causes—Mayo Clinic. (n.d.). Retrieved October 29, 2023, from https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/symptoms-causes/syc-20353378
Mxpule. (2011). English: Chimeric antigen receptor. Own work. https://commons.wikimedia.org/wiki/File:CAR_cartoon.png
Naeimi Kararoudi, M., Likhite, S., Elmas, E., Yamamoto, K., Schwartz, M., Sorathia, K., De Souza Fernandes Pereira, M., Sezgin, Y., Devine, R. D., Lyberger, J. M., Behbehani, G. K., Chakravarti, N., Moriarity, B. S., Meyer, K., & Lee, D. A. (2022). Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Reports Methods, 2(6), 100236. https://doi.org/10.1016/j.crmeth.2022.100236
Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C., & Zhu, Z. (2022). CAR race to cancer immunotherapy: From CAR T, CAR NK to CAR macrophage therapy. Journal of Experimental & Clinical Cancer Research, 41(1), 119. https://doi.org/10.1186/s13046-022-02327-z
Paul, S., & Lal, G. (2017). The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Frontiers in Immunology, 8, 1124. https://doi.org/10.3389/fimmu.2017.01124
Pegram, H. J., Andrews, D. M., Smyth, M. J., Darcy, P. K., & Kershaw, M. H. (2011). Activating and inhibitory receptors of natural killer cells. Immunology and Cell Biology, 89(2), 216–224. https://doi.org/10.1038/icb.2010.78
Pende, D., Falco, M., Vitale, M., Cantoni, C., Vitale, C., Munari, E., Bertaina, A., Moretta, F., Del Zotto, G., Pietra, G., Mingari, M. C., Locatelli, F., & Moretta, L. (2019). Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Frontiers in Immunology, 10. https://www.frontiersin.org/articles/10.3389/fimmu.2019.01179
Pfefferle, A., Jacobs, B., Haroun-Izquierdo, A., Kveberg, L., Sohlberg, E., & Malmberg, K.-J. (2020). Deciphering Natural Killer Cell Homeostasis. Frontiers in Immunology, 11, 812. https://doi.org/10.3389/fimmu.2020.00812
Philadelphia, T. C. H. of. (2014, March 30). Tunneled Central Line (Tunneled Central Venous Catheter) [Text]. The Children’s Hospital of Philadelphia. https://www.chop.edu/treatments/tunneled-central-line
Philadelphia, T. C. H. of. (2016, January 21). T Cell Collection by Apheresis [Text]. The Children’s Hospital of Philadelphia. https://www.chop.edu/services/t-cell-collection-apheresis
Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system. (n.d.). Retrieved October 29, 2023, from https://star-protocols.cell.com/protocols/1888
Rahim, M. M. A., Tu, M. M., Mahmoud, A. B., Wight, A., Abou-Samra, E., Lima, P. D. A., & Makrigiannis, A. P. (2014). Ly49 Receptors: Innate and Adaptive Immune Paradigms. Frontiers in Immunology, 5, 145. https://doi.org/10.3389/fimmu.2014.00145
Rajkumar, S. V. (2022). Multiple Myeloma: 2022 update on Diagnosis, Risk-stratification and Management. American Journal of Hematology, 97(8), 1086–1107. https://doi.org/10.1002/ajh.26590
Sadelain, M., Brentjens, R., & Riviere, I. (2013). The basic principles of chimeric antigen receptor (CAR) design. Cancer Discovery, 3(4), 388–398. https://doi.org/10.1158/2159-8290.CD-12-0548
Sameer, A. S., & Nissar, S. (2021). Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. BioMed Research International, 2021, 1157023. https://doi.org/10.1155/2021/1157023
Sanseviero, E. (2019). NK Cell-Fc Receptors Advance Tumor Immunotherapy. Journal of Clinical Medicine, 8(10), 1667. https://doi.org/10.3390/jcm8101667
Shah, U. A., & Mailankody, S. (2020). CAR T and CAR NK cells in multiple myeloma: Expanding the targets. Best Practice & Research. Clinical Haematology, 33(1), 101141. https://doi.org/10.1016/j.beha.2020.101141
Thorburn, A. (2007). Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Pathway Signaling. Journal of Thoracic Oncology, 2(6), 461–465. https://doi.org/10.1097/JTO.0b013e31805fea64
Types of multiple myeloma | Canadian Cancer Society. (n.d.). Retrieved October 29, 2023, from https://cancer.ca/en/cancer-information/cancer-types/multiple-myeloma/what-is-multiple-myeloma/types-of-multiple-myeloma
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008). Functions of natural killer cells. Nature Immunology, 9(5), Article 5. https://doi.org/10.1038/ni1582
What are NK (natural killer cell) Cell Receptors. (n.d.). CUSABIO. Retrieved October 29, 2023, from https://www.cusabio.com/receptor/NK-Cell-Receptor.html
What is CAR NK therapy? | MD Anderson Cancer Center. (n.d.). Retrieved October 29, 2023, from https://www.mdanderson.org/cancerwise/car-nk-therapy-offers-new-treatment-option-for-blood-cancers.h00-159379578.html
What You Need to Know About Multiple Myeloma. (n.d.). Retrieved October 29, 2023, from https://mnoncology.com/resources/blog/what-you-need-to-know-about-multiple-myeloma
Zhang, A., Sun, Y., Du, J., Dong, Y., Pang, H., Ma, L., Si, S., Zhang, Z., He, M., Yue, Y., Zhang, X., Zhao, W., Pi, J., Chang, M., Wang, Q., & Zhang, Y. (2021). Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release. Frontiers in Immunology, 12, 724211. https://doi.org/10.3389/fimmu.2021.724211
Zhang, L., Meng, Y., Feng, X., & Han, Z. (2022). CAR-NK cells for cancer immunotherapy: From bench to bedside. Biomarker Research, 10(1), 12. https://doi.org/10.1186/s40364-022-00364-6
Downloads
Posted
Categories
License
Copyright (c) 2023 Samuel Huang
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.